gene_symbol
CD2
hgnc_id
HGNC:1639
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Siplizumab binds CD2 on target cells and recruits immune effectors via its Fc to trigger ADCC and complement-dependent cytotoxicity, leading to lysis/depletion of CD2+ cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
Target expressed on T cells and NK cells; depletion via Fc-mediated ADCC/CDC
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT06078696
disease_id_num_tar_ref
5652
drug_id_num_tar_ref
15351